JP2009536934A - １７−オキシマクベシン誘導体並びに癌及び／又はｂ−細胞性悪性疾患の治療におけるそれらの使用 - Google Patents

１７−オキシマクベシン誘導体並びに癌及び／又はｂ−細胞性悪性疾患の治療におけるそれらの使用 Download PDF

Info

Publication number
JP2009536934A
JP2009536934A JP2009508382A JP2009508382A JP2009536934A JP 2009536934 A JP2009536934 A JP 2009536934A JP 2009508382 A JP2009508382 A JP 2009508382A JP 2009508382 A JP2009508382 A JP 2009508382A JP 2009536934 A JP2009536934 A JP 2009536934A
Authority
JP
Japan
Prior art keywords
oxymacbecin
compound
post
macbecin
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2009508382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536934A5 (enExample
Inventor
マルチン クフリスチネ
ズハング ミング
ガイスセル サビネ
コアテス ニゲル
Original Assignee
バイオチカ テクノロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオチカ テクノロジー リミテッド filed Critical バイオチカ テクノロジー リミテッド
Publication of JP2009536934A publication Critical patent/JP2009536934A/ja
Publication of JP2009536934A5 publication Critical patent/JP2009536934A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2009508382A 2006-05-09 2007-05-09 １７−オキシマクベシン誘導体並びに癌及び／又はｂ−細胞性悪性疾患の治療におけるそれらの使用 Abandoned JP2009536934A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0609117.7A GB0609117D0 (en) 2006-05-09 2006-05-09 Novel compounds
PCT/EP2007/054473 WO2007128827A1 (en) 2006-05-09 2007-05-09 17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies

Publications (2)

Publication Number Publication Date
JP2009536934A true JP2009536934A (ja) 2009-10-22
JP2009536934A5 JP2009536934A5 (enExample) 2010-05-27

Family

ID=36637122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009508382A Abandoned JP2009536934A (ja) 2006-05-09 2007-05-09 １７−オキシマクベシン誘導体並びに癌及び／又はｂ−細胞性悪性疾患の治療におけるそれらの使用

Country Status (11)

Country Link
US (1) US20100068203A1 (enExample)
EP (1) EP1940798A1 (enExample)
JP (1) JP2009536934A (enExample)
KR (1) KR20090005377A (enExample)
CN (1) CN101437802A (enExample)
AU (1) AU2007247119A1 (enExample)
BR (1) BRPI0711092A2 (enExample)
CA (1) CA2651557A1 (enExample)
GB (1) GB0609117D0 (enExample)
MX (1) MX2008014279A (enExample)
WO (1) WO2007128827A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9967590B2 (en) 2008-04-10 2018-05-08 Qualcomm Incorporated Rate-distortion defined interpolation for video coding based on fixed filter or adaptive filter

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160175A1 (en) * 2006-09-11 2011-06-30 Christine Martin 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CN110999828A (zh) * 2019-12-19 2020-04-14 上海海洋大学 改变鱼类体色分布模式的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2146668A1 (en) * 1992-10-14 1994-04-28 Luke Whitesell Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
EP0828418A4 (en) * 1995-05-02 2000-03-29 Univ California INDUCTION OF THERMOTOLERANCE WITH BENZOCHINOIDS ANSAMYCINES

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9967590B2 (en) 2008-04-10 2018-05-08 Qualcomm Incorporated Rate-distortion defined interpolation for video coding based on fixed filter or adaptive filter
US10440388B2 (en) 2008-04-10 2019-10-08 Qualcomm Incorporated Rate-distortion defined interpolation for video coding based on fixed filter or adaptive filter
US11683519B2 (en) 2008-04-10 2023-06-20 Qualcomm Incorporated Rate-distortion defined interpolation for video coding based on fixed filter or adaptive filter

Also Published As

Publication number Publication date
GB0609117D0 (en) 2006-06-21
WO2007128827A8 (en) 2008-01-03
US20100068203A1 (en) 2010-03-18
MX2008014279A (es) 2008-11-26
CA2651557A1 (en) 2007-11-15
EP1940798A1 (en) 2008-07-09
BRPI0711092A2 (pt) 2011-08-23
WO2007128827A1 (en) 2007-11-15
KR20090005377A (ko) 2009-01-13
AU2007247119A1 (en) 2007-11-15
CN101437802A (zh) 2009-05-20

Similar Documents

Publication Publication Date Title
US20090209494A1 (en) 21-deoxymacbecin analogues useful as antitumor agents
JP2009536181A (ja) 癌治療用の１８，２１−ジデスオキシマクベシン誘導体
JP2009536934A (ja) １７−オキシマクベシン誘導体並びに癌及び／又はｂ−細胞性悪性疾患の治療におけるそれらの使用
JP2010509307A (ja) ガンの治療のための１８，２１−ジデスオキシマクベシン誘導体
EP1973883B1 (en) Novel compounds and methods for their production
US20090117127A1 (en) Novel Compounds and Methods for Their Production
US20090209507A1 (en) 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20110091452A1 (en) 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20090298804A1 (en) Novel Compounds and Methods for Their Production
JP2010520190A (ja) 新規化合物
EP2079700A1 (en) 18, 21-didesoxymacbecin derivatives for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100407

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20110120